Hunter Perkins Capital Management LLC Acquires Shares of 7,100 Haemonetics Corporation $HAE

Hunter Perkins Capital Management LLC bought a new stake in Haemonetics Corporation (NYSE:HAE - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,100 shares of the medical instruments supplier's stock, valued at approximately $530,000.

Other large investors have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd bought a new stake in shares of Haemonetics in the 1st quarter worth about $468,000. AQR Capital Management LLC increased its holdings in Haemonetics by 591.6% in the first quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier's stock valued at $10,931,000 after buying an additional 149,325 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Haemonetics by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier's stock valued at $3,543,000 after buying an additional 7,678 shares in the last quarter. Royal Bank of Canada raised its stake in Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier's stock valued at $68,355,000 after buying an additional 24,650 shares in the last quarter. Finally, Invenomic Capital Management LP bought a new position in Haemonetics during the 1st quarter worth approximately $6,783,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Up 3.0%

Haemonetics stock opened at $50.39 on Monday. The firm has a market capitalization of $2.43 billion, a P/E ratio of 15.41, a P/E/G ratio of 0.93 and a beta of 0.37. The company has a 50-day simple moving average of $56.18 and a 200-day simple moving average of $63.67. Haemonetics Corporation has a one year low of $47.31 and a one year high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. During the same period in the previous year, the business posted $1.02 EPS. Haemonetics's revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, equities analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup upgraded Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a report on Wednesday, July 9th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Haemonetics in a research note on Saturday, September 27th. Robert W. Baird assumed coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target on the stock. Mizuho decreased their price target on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Finally, Raymond James Financial lowered shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and dropped their price objective for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $78.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.